RT Journal Article SR Electronic T1 Elevated Serum Concentrations of Triggering Receptor Expressed on Myeloid Cells-1 in Diffuse Cutaneous Systemic Sclerosis: Association with Severity of Pulmonary Fibrosis JF The Journal of Rheumatology JO J Rheumatol FD The Journal of Rheumatology SP 787 OP 791 DO 10.3899/jrheum.090664 VO 37 IS 4 A1 HAJIME TOMITA A1 FUMIHIDE OGAWA A1 TOSHIHIDE HARA A1 KOICHI YANABA A1 YOHEI IWATA A1 EIJI MUROI A1 AYUMI YOSHIZAKI A1 KAZUHIRO KOMURA A1 MOTOI TAKENAKA A1 KAZUHIRO SHIMIZU A1 MINORU HASEGAWA A1 MANABU FUJIMOTO A1 SHINICHI SATO YR 2010 UL http://www.jrheum.org/content/37/4/787.abstract AB Objective. To determine serum concentrations and clinical association of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in patients with systemic sclerosis (SSc). Methods. Serum sTREM-1 levels from 17 patients with limited cutaneous SSc (lSSc), 24 patients with diffuse cutaneous SSc (dSSc), and 29 healthy control individuals were examined by ELISA. Results. Total SSc patients exhibited significantly elevated serum sTREM-1 levels relative to controls (p < 0.01). Serum sTREM-1 levels were significantly elevated in patients with dSSc compared to controls (p < 0.005) and lSSc patients (p < 0.05). By contrast, sTREM-1 levels in lSSc were similar to those in controls. Serum sTREM-1 levels were significantly elevated in SSc patients with decreased percentage vital capacity (%VC). Consistent with this, serum sTREM-1 levels in SSc patients correlated negatively with %VC (r = −0.24, p < 0.005). Among SSc patients with pulmonary fibrosis, sTREM-1 levels were significantly increased in patients with decreased %VC or decreased percentage of diffusion capacity for carbon monoxide relative to those with normal values (p < 0.05). Conclusion. Serum sTREM-1 levels were elevated in dSSc patients and correlated with severity of pulmonary fibrosis, suggesting that serum sTREM-1 is a novel serological marker for the disease severity of SSc.